c.jpg)
Profile
Heading the state of art facility and infrastructure for vaccine R & D, addressing pandemic preparedness. Research focused towards novel target validation, vaccine discovery, antibody discovery and development platform and structural biology. We aim towards understanding the antigenic signature, structure delineation and immune-dominant epitope, sequence variations to understand the mutational hotspots generated over the time. Targeting the innovative approaches my research aim to bridge the gap of translational research and bio-therapeutics development
Current Focus Areas
Vaccine Research, Virology, Protein Translational product, Antibody discovery, Structure biology, epitope focused vaccine candidate
Selected Publications
Recent/Relevant Publications (5), 1. Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model. Frontiers in Immunology (first and corresponding author), 24 May 2021, https: //doi.org/ 10.3389/ fimmu.2021.641447 [IF: 7.561] 2. Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus. Int Immunopharmacol. 2021 Oct;99:108020 (Co-First Author) [IF: 4.932] 3. A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern. PLoS Pathog. 2022 Dec 12;18(12):e1010994. doi: 10.1371/journal.ppat.1010994. eCollection 2022 Dec. 4. Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARSCoV-2 and variants of concern. Nature Microbiology, 2022 Jun 9. doi: 10.1038/s41564-022-01161-5. [IF: 17.74] 5. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis. 2021 Nov 25;S1473-3099(21)00680-0 [IF: 25ยท071]